➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Moodys
AstraZeneca
Harvard Business School
McKinsey

Last Updated: August 9, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TRANDATE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Trandate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02050529 Randomized Clinical Trial of Labetalol Versus Hydralazine for Severe Hypertension in Obstetric Patients. Unknown status Dow University of Health Sciences Phase 2/Phase 3 2013-02-01 Severe Hypertension in pregnancy demands urgent treatment because of high mortality & morbidity in obstetric patients. Hydralazine, the most commonly used agent, causes sudden hypotension and tachycardia. Labetalol because of combined α and β blocking effects lacks these side effects. Cochrane systematic review could include only three trials of comparison of hydralazine with labetalol. All three had sample size ranging from 20-60 obstetric, including 19-30 pregnant women. This review could not conclude about comparative effects due to insufficient data and suggested that further trials should compare hydralazine with nifedipine or labetalol, and to report severe persistent hypertension and adverse feto-maternal effects. OBJECTIVES:1) To compare efficacy of labetalol versus hydralazine for control of pregnancy related severe hypertension.2) To compare adverse maternal and fetal effects of the two drugs. 3) Furthermore, to develop risk assessment model for response to treatment, in terms of patient and disease characteristics. STUDY DESIGN: Randomized controlled trial. SETTING & DURATION OF STUDY: Gynaecology Unit I, Civil hospital Karachi over a period of 1 year. METHODS: Total one hundred eighty patients with, severe hypertension(systolic blood pressure(SBP)≥160 and/or diastolic blood pressure(DBP) ≥110 mm Hg) at greater than 28 weeks of pregnancy or upto72 hours after delivery, will be enrolled. In each group 90 patients will be allocated to intravenous labetalol or hydralazine using simple random sampling. Primary outcome measures will be lowering of SBP to <160 mm Hg and DBP <110 mm Hg and severe persistent hypertension. In addition maternal hypotension, tachycardia, bradycardia, adverse effect on fetal heart, still birth and neonatal bradycardia will be measured. EXPECTED OUTCOME: Efficacy and side effects of labetalol against hydralazine, in our population will be determined. Assessment model for response to treatment, will help in choosing a drug with better efficacy and minimal side effect profile for different patient and disease profiles.
NCT02135315 Intensive Arterial Pressure Control in Acute Coronary Syndrome Unknown status Emergency NGO Onlus Phase 0 2013-10-01 The intensive arterial pressure control in acute coronary syndrome (ACS) during the first 24 hours can improve the prognosis in the short and long term. We confront two treatment strategies (standard and intensive treatment) to evaluate their superiority in the treatment of acute coronary syndrome.
NCT02135315 Intensive Arterial Pressure Control in Acute Coronary Syndrome Unknown status University of Monastir Phase 0 2013-10-01 The intensive arterial pressure control in acute coronary syndrome (ACS) during the first 24 hours can improve the prognosis in the short and long term. We confront two treatment strategies (standard and intensive treatment) to evaluate their superiority in the treatment of acute coronary syndrome.
NCT02531490 Early Vascular Adjustments During Hypertensive Pregnancy Recruiting Maastricht University Medical Center Phase 4 2015-12-01 Paradoxical fetal and maternal results of studies have led to inconsistent use of antihypertensive drugs or no treatment at all in mild to moderate gestational hypertension in the Netherlands. However, none of the studies have taken the individual maternal circulatory state or the contemplated blood pressure response into account. Hypertension may be accompanied by high (hyperdynamic vasodilated profile), normal (normodynamic profile) of low (hypodynamic vasoconstrictive profile) cardiac output, and preeclampsia is not restricted to one circulatory profile. Therefore antihypertensive drugs should be viewed upon as correctors of the hemodynamic state rather than solely reducers of blood pressure. Without taking the maternal hemodynamic profile and condition into account, generic antihypertensive treatment can be expected to result in disappointing, inadequate and paradoxical results. The investigators hypothesize that in mild to moderate hypertension, personalized hemodynamically guided antihypertensive therapy (with target systolic and diastolic blood pressure <130/80mmHg), prevents the progression to severe hypertension and/or preeclampsia compared to no treatment, without the alleged side-effects.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Trandate

Condition Name

Condition Name for Trandate
Intervention Trials
Preeclampsia 2
Pre-eclampsia 2
Hypertension, Pregnancy-Induced 2
Chronic Hypertension Complicating Pregnancy (Diagnosis) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Trandate
Intervention Trials
Pre-Eclampsia 4
Hypertension, Pregnancy-Induced 3
Hypertension 3
Eclampsia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Trandate

Trials by Country

Trials by Country for Trandate
Location Trials
United States 3
Tunisia 1
Pakistan 1
Netherlands 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Trandate
Location Trials
Tennessee 2
Ohio 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Trandate

Clinical Trial Phase

Clinical Trial Phase for Trandate
Clinical Trial Phase Trials
Phase 4 2
Phase 2/Phase 3 1
Phase 0 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Trandate
Clinical Trial Phase Trials
Recruiting 3
Unknown status 2
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Trandate

Sponsor Name

Sponsor Name for Trandate
Sponsor Trials
Maastricht University Medical Center 1
University of Monastir 1
Emergency NGO Onlus 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Trandate
Sponsor Trials
Other 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Express Scripts
McKinsey
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.